Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, Kupfer S, Perez A, Nesto R, Nissen SE. Nicholls SJ, et al. Among authors: wolski k. J Am Coll Cardiol. 2011 Jan 11;57(2):153-9. doi: 10.1016/j.jacc.2010.06.055. J Am Coll Cardiol. 2011. PMID: 21211686 Free article. Clinical Trial.
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators. Saw J, et al. Among authors: wolski k. J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9. doi: 10.1016/j.jacc.2004.06.049. J Am Coll Cardiol. 2004. PMID: 15364319 Free article. Clinical Trial.
Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.
Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM. Gurm HS, et al. Among authors: wolski k. J Am Coll Cardiol. 2005 Jun 21;45(12):1932-8. doi: 10.1016/j.jacc.2005.02.074. J Am Coll Cardiol. 2005. PMID: 15963389 Free article. Clinical Trial.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Nissen SE, et al. Among authors: wolski k. JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13. JAMA. 2006. PMID: 16533939 Clinical Trial.
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, Sipahi I, Nicholls SJ, Magyar WA, Loyd A, Churchill T, Crowe T, Nissen SE. Schoenhagen P, et al. Among authors: wolski k. Circulation. 2006 Jun 20;113(24):2826-34. doi: 10.1161/CIRCULATIONAHA.105.585703. Epub 2006 Jun 12. Circulation. 2006. PMID: 16769916 Clinical Trial.
Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.
Nicholls SJ, Sipahi I, Schoenhagen P, Wisniewski L, Churchill T, Crowe T, Goormastic M, Wolski K, Tuzcu EM, Nissen SE; ACTIVATE Investigators. Nicholls SJ, et al. Among authors: wolski k. Am Heart J. 2006 Jul;152(1):67-74. doi: 10.1016/j.ahj.2005.10.025. Am Heart J. 2006. PMID: 16824833
234 results